Nigeria’s top players compete at second Wiser Squash Invitational in Abuja

Sunday, May 8, 2022

Gabriel Olufunmilayo and Busayo Olatunji

Gabriel Olufunmilayo and Busayo Olatunji

Gabriel Olufunmilayo and Busayo Olatunji have won the second edition of the Wiser Squash Invitational in Abuja.

Olufunmilayo defeated Adegoke Onaopemipo 3-1 (11/5, 11/8, 5/11, 11/9) on Saturday to defend his title in the men’s category.

Similarly, Olatunji fought hard to see off Rofiat Abdulazeez 3-2 (11/13, 11/6, 12/10, 5/11 11/1) in the women’s event.

Olufunmilayo, who is Nigeria’s second ranked male player, acknowledged that the game against Onaopemipo, Nigeria’s number one, was a tough one.

“I tried to give my best. It wasn’t an easy game for me at all because Onaopemipo is a strong player. He has beaten me three times this year and I felt it’s time to take my pound of flesh.

“I had to win, I noticed he had a cramp at some point and I guess it worked to my advantage. I had an issue with my groin as well but I just had to win,” Olufunmilayo said.

On her part, Olatunji, the country’s top ranked female player, was thankful with her victory against second ranked Abdulazeez, adding that she lost concentration in the game at some point.

“I am very happy to have won the game. It was a tough game and I lost concentration and was leading 2-1, but it soon became a tie.

“So, I’m happy to have won and gained more Professional Squash Association (PSA) points,” she said.

Fifty players took part in the event, organised to help Nigerian players gain PSA points.

(NAN)

  • In an era of fake news and overcrowded media marketplace, the journalists at Peoples Gazette aim to provide quality and practical information to help our readers stay ahead and better understand events around them. We focus on being the balanced source of true, stimulating and independent journalism.
  • The Peoples Gazette Ltd, Plot 1095, Umar Shuaibu Avenue, Utako, Abuja.
  • +234 805 888 8330.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Akwa Ibom gets new NYSC coordinator thumbnail

Akwa Ibom gets new NYSC coordinator

Advertisement The National Youth Service Corps, NYSC, Akwa Ibom State, has received its 19th state coordinator, Mr Christopher Okun. Okun succeeds Mrs Chinyere Ekwe, who has been redeployed to the NYSC Area Office in Minna, Niger State, after the expiration of her tenure. A statement signed by NYSC Public Relations Officer, Mr Udogwu Madukaku, on
Read More
LOL! Even more classified documents found at Biden's Wilmington home thumbnail

LOL! Even more classified documents found at Biden’s Wilmington home

This entire Biden classified documents scandal is hilarious. In typical fashion, the Left went full ‘Chicken Little, treasonous threat to the Republic’ clown show when the Trump Mar-a-Lago classified document story broke.Now, they’re stuck trying to figure out how to excuse Biden for apparently having held onto classified documents for decades while still maintaining their
Read More
transgender father thumbnail

transgender father

Der ehemalige „The Guardian“-Journalist Freddy McConnell (36) lebt seit über einem Jahrzehnt als Mann. Er ist Transgender, kam also mit weiblichen Geschlechtsmerkmalen zur Welt und begann vor zwölf Jahren mit seiner Geschlechtsangleichung. In Großbritannien ist McConnell rechtlich seit Jahren als Mann anerkannt. Er ließ sich das Brustgewebe entfernen, nahm Testosteron, behielt aber seine weiblichen Fortpflanzungsorgane.…
Read More
〈虎年景氣展望前瞻〉三家新藥臨床試驗入尾聲 年後解盲邁向新里程碑 thumbnail

〈虎年景氣展望前瞻〉三家新藥臨床試驗入尾聲 年後解盲邁向新里程碑

台睿、逸達、寶齡等三家新藥臨床試驗入尾聲。(圖:AFP)Tag台睿敗血症逸達新藥新冠新藥寶齡腎病拿百磷台灣生技廠新藥歷經多年開發,多項新藥臨床試驗預計農曆春節後公布結果,包括台睿 (6580-TW) 的敗血症用藥、逸達 (6576-TW) 旗下治療 COVID-19 重症 (重度症狀) 新冠新藥,以及寶齡富錦 (1760-TW) 腎病新藥拿百磷中國臨床試驗等都將進入尾聲,新藥解盲結果將為產業邁向另一里程碑。 台睿敗血症用藥 Rexis 三期臨床試驗,已於去年中完成 330 人收案,其合作的 7 家醫學中心同步整理臨床數據中,針對主要指標死亡率與次要指標副作用等進行分析,若解盲結果正向,預計 2023 年取得台灣藥證,並成為全球首個上市的抗敗血病新藥。 台睿除了搶攻台灣 12.6 萬名敗血症病患、逾 5 億元商機外,也將進軍美國市場,去年底向美國 FDA 提出臨床試驗申請,預計會從二期臨床試驗開始執行,擬採開放性試驗設計。 逸達新成分新藥 FP-025 用於治療 COVID-19 重症急性呼吸窘迫症候群 (ARDS) 第二 / 三期臨床試驗,為加速收案,除了持續在美國多個醫學中心進行外,去年第四季新增中南美洲、印度等受試基地,目標本季底完成招募 99 位受試者。 目前 ARDS 主要療法是透過呼吸器協助病患得到足夠氧氣,逸達指出,新冠新藥完成收案、病患服藥 28 天後可進行主要分析,病患的存活率與是否需要呼吸器成分析指標。 寶齡腎病新藥拿百磷已在台灣、美國、日本、歐洲等地區銷售,在中國執行的三期臨床試驗已於去年底完成,預計本季底前解盲,此外,寶齡中國合作夥伴山東威高為中國最大洗腎醫材供應商,市占率高達 9 成,若新藥順利解盲、取證,有望進一步挹注成長動能。 延伸閱讀台睿攜手共信開發抗癌新藥 放眼中國市場逸達氣喘新藥二期期中分析達標 明年中完成最終試驗逸達前列腺癌新劑型新藥 獲加拿大上市許可逸達新冠新藥臨床完成審查 明年首季完成收案台睿明年兩大產品有斬獲 敗血症新藥農曆年後解盲寶齡乾洗手產品未哄抬價格 經營秉持誠信原則特此澄清逸達前列腺癌新劑型新藥中國臨床進入審查 最快兩年完成寶齡快篩經台大醫院證實可偵測Omicron 準確率超過9成
Read More
Index Of News
Total
0
Share